According to the American Heart Association (AHA), A, B, and AB blood types are associated with a greater risk of dangerous ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks ...

Highlights of the conference coverage from the 2025 European Society of Medical Oncology (ESMO) Congress included content on ...

The deal gives clinicians in PathNet's national lab network access to Valar's AI-powered Vesta diagnostic portfolio for non-muscle invasive bladder cancer.

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Valar Labs, a leader in AI-powered diagnostics for oncology, today announced a strategic partnership with PathNet Lab, one of the nation's foremost pathology laboratories. Through this collaboration, ...

Over the year multiple clinical trial readouts validated the use of MRD for multiple indications, while companies in the space began to consolidate.

Triage Plus was designed to detect mRNAs and DNA single-nucleotide variants from fibroblast growth factor receptor 3 and telomerase reverse transcriptase genes associated with bladder cancer.

Urology Department, The First Affiliated Hospital of Yangtze University, Jingzhou, China. Bladder cancer represents a widespread malignant neoplasm globally, characterized by a notable rate of ...

ABSTRACT: Bladder cancer represents a widespread malignant neoplasm globally, characterized by a notable rate of recurrence following the initial diagnosis and treatment. Traditional methods for ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed ...